Table II.

Uni- and multivariate analyses of association between various factors and overall survival in 271 patients with metastatic renal cell carcinoma who were treated with tyrosine kinase inhibitor.

	Univariate analysis		Multivariate analysis
Factors	Hazard ratio	P-value	Hazard ratio	P-value
Age, years (<60 vs. ≥60)	1.02	0.92	–	–
Gender (male vs. female)	1.47	0.15	–	–
Prior immunotherapy (yes vs. no)	1.37	0.10	–	–
MSKCC classification (poor vs. favorable or intermediate)	4.31	<0.001	1.73	0.038
C-reactive protein, mg/dl (≥1.0 vs. <1.0)	3.69	<0.001	2.80	<0.001
Lung metastasis (yes vs. no)	1.16	0.45	–	–
Lymph node metastasis (yes vs. no)	1.59	0.014	1.12	0.57
Bone metastasis (yes vs. no)	1.67	0.026	1.14	0.51
Liver metastasis (yes vs. no)	3.08	<0.001	2.37	0.0030
Brain metastasis (yes vs. no)	1.09	0.78	–	–
Histological subtype (clear cell carcinoma vs. others)	1.66	0.030	1.04	0.88
Sarcomatoid characteristics (yes vs. no)	2.45	<0.001	1.55	0.082

MSKCC, Memorial Sloan-Kettering Cancer Center.